Search

everythinglearnresearchcommunity

for

Search:↓

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

The post discusses Dr. Rassman's advice on microneedling for hair loss, suggesting holding a Dr Pen with 36 needles in one spot for 10 seconds. The conversation includes differing opinions on this method, with one user explaining the importance of dipping the pen rather than swiping to avoid abrasions.

The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

User experienced shedding and bald spots after 1 month of using Redensyl. Considering trying CosmeRNA as alternative treatment.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Pyrilutamide powder is now available at a local supermarket in the Netherlands. The discussion humorously touches on hair loss treatments like Minoxidil, finasteride, and RU58841.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Microneedle pens for hair loss are harder to find on Amazon due to FDA regulations on needle length. Users suggest buying from AliExpress or Temu instead.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation is about using DIY copper peptide (GHK CU) serum for microneedling to address hair loss, with additional treatments including Nizoral for DHT reduction and red light therapy. The user is considering adding Minoxidil but is concerned due to having cats.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.